Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.19.1
Earnings (Loss) Per Common Share (Tables)
 9 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):
 
 
 
Three Months ended

March 31,
 
 
Nine Months ended

March 31,
 
 
 
2019
 
 
2018
 
 
2019
 
 
2018
 
Basic and diluted numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss attributable to iBio, Inc.
 
$
(4,223
)
 
$
(3,962
)
 
$
(13,090
)
 
$
(11,687
)
  Preferred stock dividends
 
 
64
 
 
 
64
 
 
 
195
 
 
 
195
 
Net loss available to iBio, Inc. stockholders
 
$
(4,287
)
 
$
(4,026
)
 
$
(13,285
)
 
$
(11,882
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
 
19,224
 
 
 
11,545
 
 
 
18,597
 
 
 
10,247
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Per share amount
 
$
(0.22
)
 
$
(0.35
)
 
$
(0.71
)
 
$
(1.16
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] As of March 31, 2019 and 2018, shares issuable which could potentially dilute future earnings were as follows:
 
 
 
Three and Nine

Months Ended

December 31,
 
 
 
2019
 
 
2018
 
 
 
(in thousands)
 
Stock options
 
 
947
 
 
 
1,350
 
Series A Preferred
 
 
4,980
 
 
 
-
 
Series B Preferred
 
 
6,428
 
 
 
-
 
Shares excluded from the calculation of diluted loss per share
 
 
12,355
 
 
 
1,350